Drug
Gme751
Gme751: highest development phase Phase 3, developed by Sandoz. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| GME751 NCT06159790 | Phase 3 | Metastatic NSCLC |
| GME751 NCT06153238 | Phase 1 | Melanoma |
Latest
No recent events.
Follow Gme751 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.